- Home
- VYGR vs ACB Comparison
VYGR vs ACB Comparison
Compare VYGR & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- ACB
- Stock Information
- Founded
- VYGR 2013
- ACB 2013
- Country
- VYGR United States
- ACB Canada
- Employees
- VYGR N/A
- ACB N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- ACB Pharmaceuticals and Biotechnology
- Sector
- VYGR Health Care
- ACB Health Care
- Exchange
- VYGR Nasdaq
- ACB Nasdaq
- Market Cap
- VYGR 222.9M
- ACB 234.9M
- IPO Year
- VYGR 2015
- ACB N/A
- Fundamental
- Price
- VYGR $3.16
- ACB $4.44
- Analyst Decision
- VYGR Strong Buy
- ACB Hold
- Analyst Count
- VYGR 9
- ACB 1
- Target Price
- VYGR $14.86
- ACB N/A
- AVG Volume (30 Days)
- VYGR 396.9K
- ACB 1.0M
- Earning Date
- VYGR 05-12-2025
- ACB 02-05-2025
- Dividend Yield
- VYGR N/A
- ACB N/A
- EPS Growth
- VYGR N/A
- ACB N/A
- EPS
- VYGR N/A
- ACB 0.07
- Revenue
- VYGR $80,001,000.00
- ACB $222,964,332.00
- Revenue This Year
- VYGR N/A
- ACB $28.17
- Revenue Next Year
- VYGR $2.04
- ACB $12.95
- P/E Ratio
- VYGR N/A
- ACB $69.63
- Revenue Growth
- VYGR N/A
- ACB 20.72
- 52 Week Low
- VYGR $2.75
- ACB $3.42
- 52 Week High
- VYGR $9.55
- ACB $9.35
- Technical
- Relative Strength Index (RSI)
- VYGR 38.34
- ACB 51.20
- Support Level
- VYGR $2.75
- ACB $4.16
- Resistance Level
- VYGR $3.34
- ACB $4.50
- Average True Range (ATR)
- VYGR 0.26
- ACB 0.28
- MACD
- VYGR 0.03
- ACB 0.04
- Stochastic Oscillator
- VYGR 41.41
- ACB 89.61
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.